Tetrathiomolybdate

四硫钼酸铵

Report date: 2023/04/25 13:58:51
NME

Base Information

Drug NameTetrathiomolybdate
Drug Alias NameTiomolibdic acid ammonium salt硫代钼酸盐四硫钼酸盐Ammonium tetrathiomolybdate四硫代钼酸盐 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransforming growth factor beta inhibitorsFibroblast growth factors antagonistsVascular endothelial growth factor inhibitors
TargetsFibroblast growth factorsTransforming growth factor betaVascular endothelial growth factor
Therapy Area/IndicationsPsoriasisIdiopathic Pulmonary FibrosisHepatolenticular Degeneration +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Michigan
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteDartmouth-Hitchcock Medical Center
Inactive CompaniesWeill Medical College of Cornell UniversityRoswell Park Cancer InstituteUniversity Of Rochester +[6] 
Active IndicationsNeoplasm, ResidualTriple Negative Breast Neoplasms
Inactive IndicationsPsoriasisIdiopathic Pulmonary FibrosisHepatolenticular Degeneration +[10] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank